Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to TARSA's fourth quarter and full year 2025 financial results conference call. As a reminder, this call is being recorded, and all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin. Thank you. Before we begin, I encourage everyone to visit the investor section of the TARCIS website to see the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Matawala, our Chief Commercial Officer, Stacia Nirvanan, our Chief Operating Officer, and Jeff Farah, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I'll turn the call over to Bobby. Good afternoon, and thank you for joining us. 2025 was a breakout year for Tarsus and for Xtembe. the first and only FDA-approved therapeutic for demonex blepharitis, an impactful disease that affects more than 25 million Americans. Among the key highlights for the year, we delivered more than $450 million in full-year net sales. We have helped more than half a million patients living with demonex blepharitis since launch, underscoring the meaningful real-world impa...